Reported about 23 hours ago
Geron Corp. (NASDAQ:GERN), a biopharmaceutical firm focused on oncology, is highlighted as one of the most promising penny stocks by analysts, ranking fifth in this category. With a share price of $1.32 and an impressive average upside potential of over 240%, the company has seen significant revenue from its drug RYTELO, which is expected to gain EU approval. Despite market uncertainties, analysts remain optimistic about investment opportunities in GERN and suggest leveraging current conditions for potential gains.
Source: YAHOO